Pieris Pharmaceuticals, Inc. – NASDAQ:PIRS
Pieris Pharmaceuticals stock price today
$13.26
-0.33
-2.5%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Pieris Pharmaceuticals stock price monthly change
+98.54%
month
Pieris Pharmaceuticals stock price quarterly change
+98.54%
quarter
Pieris Pharmaceuticals stock price yearly change
+9614.29%
year
Pieris Pharmaceuticals key metrics
Market Cap | 17.95M |
Enterprise value | 30.01M |
P/E | -2.11 |
EV/Sales | 0.73 |
EV/EBITDA | -0.57 |
Price/Sales | 1.38 |
Price/Book | 2.01 |
PEG ratio | -0.06 |
EPS | -12.73 |
Revenue | 40.92M |
EBITDA | 12.02M |
Income | -16.25M |
Revenue Q/Q | -97.26% |
Revenue Y/Y | 142.89% |
Profit margin | -120.03% |
Oper. margin | -155.86% |
Gross margin | 9.11% |
EBIT margin | -155.86% |
EBITDA margin | 29.37% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePieris Pharmaceuticals stock price history
Pieris Pharmaceuticals stock forecast
Pieris Pharmaceuticals financial statements
| Jun 2023 | 20.05M | 3.97M | 19.83% |
|---|---|---|---|
| Sep 2023 | 19.52M | -10.75M | -55.08% |
| Dec 2023 | 1.29M | -4.58M | -352.89% |
| Mar 2024 | 53K | -4.89M | -9230.19% |
| 2025 | 7M | -26.29M | -375.7% |
|---|---|---|---|
| 2026 | 48.93M | -27.91M | -57.06% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 87544000 | 47.04M | 53.74% |
|---|---|---|---|
| Sep 2023 | 59376000 | 28.86M | 48.62% |
| Dec 2023 | 38680000 | 11.92M | 30.82% |
| Mar 2024 | 29497000 | 7.53M | 25.54% |
| Jun 2023 | -13.43M | -1.36M | 19.78M |
|---|---|---|---|
| Sep 2023 | -9.72M | -1.98M | 0 |
| Dec 2023 | -19.66M | 3.44M | 14K |
| Mar 2024 | -6.99M | 9M | 0 |
Pieris Pharmaceuticals alternative data
| Aug 2023 | 127 |
|---|---|
| Sep 2023 | 127 |
| Oct 2023 | 127 |
| Nov 2023 | 127 |
| Dec 2023 | 127 |
| Jan 2024 | 127 |
| Feb 2024 | 127 |
| Mar 2024 | 127 |
| Apr 2024 | 127 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
Pieris Pharmaceuticals other data
46.16%
-4.51%
of PIRS is owned by hedge funds
34.21M
-3.13M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2024 | 6001 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2023 10 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 29 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 2 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 6 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
What's the price of Pieris Pharmaceuticals stock today?
One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $13.26.
-
When is Pieris Pharmaceuticals's next earnings date?
Unfortunately, Pieris Pharmaceuticals's (PIRS) next earnings date is currently unknown.
-
Does Pieris Pharmaceuticals pay dividends?
No, Pieris Pharmaceuticals does not pay dividends.
-
How much money does Pieris Pharmaceuticals make?
Pieris Pharmaceuticals has a market capitalization of 17.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 65.28% to 42.81M US dollars.
-
What is Pieris Pharmaceuticals's stock symbol?
Pieris Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PIRS".
-
What is Pieris Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pieris Pharmaceuticals?
Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pieris Pharmaceuticals's key executives?
Pieris Pharmaceuticals's management team includes the following people:
- Mr. Stephen S. Yoder Chief Executive Officer, Pres & Director(age: 49, pay: $730,130)
- Dr. Hitto Kaufmann Ph.D. Senior Vice President & Chief Scientific Officer(age: 54, pay: $458,680)
- Mr. Thomas Bures Senior Vice President & Chief Financial Officer(age: 51, pay: $360,510)
-
How many employees does Pieris Pharmaceuticals have?
As Jul 2024, Pieris Pharmaceuticals employs 46 workers, which is 64% less then previous quarter.
-
When Pieris Pharmaceuticals went public?
Pieris Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 2 Jan 2015.
-
What is Pieris Pharmaceuticals's official website?
The official website for Pieris Pharmaceuticals is pieris.com.
-
Where are Pieris Pharmaceuticals's headquarters?
Pieris Pharmaceuticals is headquartered at 255 State Street, Boston, MA.
-
How can i contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals's mailing address is 255 State Street, Boston, MA and company can be reached via phone at 857 246 8998.
Pieris Pharmaceuticals company profile:
Pieris Pharmaceuticals, Inc.
pieris.comExchange:
NASDAQ
Full time employees:
46
Industry:
Biotechnology
Sector:
Healthcare
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
255 State Street
Boston, MA 02109
Boston, MA 02109
CIK: 0001583648
ISIN: US7207951036
CUSIP: 720795103
